IPSCSG arranges biennial collaborative meetings for researchers with a unique focus on Primary Sclerosing Cholangitis (PSC) and all its aspects. This year the event was in Boston, USA, August 29th to 30th.
Bacteria in the gut can influence how serious a liver disease becomes, according to new research. The findings strengthen the idea that signals from the gut can worsen disease in the liver, and they point to medicines that might help patients in the future.
European Association for study of the Liver arranges an annual congress, this year in Barcelona, May 27th to 30th. The EASL Congress is Europe’s largest event dedicated to liver health, with more than 8500 participants, 2000 abstracts and 190 presentations.
NoPSC has several mechanisms in place to ensure the continuous high quality of our research, one of those is the Guest Professor program.
The Norwegian Gastroenterological Society (Norsk Gastroenterologisk Forening, NGF) had its annual meeting in Lillehammer 29th to 31st of January 2026. NoPSC participated with several presentations of which three were awarded prizes.
Dr. Tine Simensen Oldereid’s work explores how host-microbiota interactions and exposures to non-viable microbial components during early life influence immune development and inflammation. Oldereid successfully defended her PhD thesis on March 6th 2026.
NoPSC collaborate with scientists around the world, including our neighboring Swedish PSC-researchers. The one-day event in Stockholm February 5th, with more than 25 PSC-researchers, strengthened this collaboration.
Dr. Marit Mæhle Grimsrud’s doctoral work is focused on the strong need for better tools that can detect cancer earlier and guide more personalized treatment in patients with PSC. Grimsrud successfully defended her PhD on December 8h 2025.
Dr. Simen Hyll Hansen successfully defended his thesis “Diagnostic and Prognostic Potential of the Gut Microbiome in Inflammatory Bowel Disease”, on December 15th 2025.
Dr. Laura Valestrand successfully defended her PhDs thesis (November 28th 2025). The thesis explores how bile and immune cells contribute to the development of cholestatic liver diseases such as primary sclerosing cholangitis (PSC).
Experiments involving gnotobiotic mice is resource-intensive and always involves a certain risk of contamination. With the new facility this risk is significantly reduced.
NoPSC researchers awarded 9 million NOK to find new drug targets and biomarkers for primary sclerosing cholangitis.
A world leading expert on cholestatic itch, Professor Kremer shed light on the underlying mechanisms and potential therapeutic strategies that could significantly improve treatment options for patients suffering from this debilitating symptom in cholestatic liver diseases.
The Research Council's commercialisation support is intended to contribute to the use of publicly funded research through increased commercial exploitation and/or societal innovation. Researchers from NoPSC will now be able to test the commercialization potential of the DUCT chip.
The official opening of the new ERC Consolidator Grant project «FatVersusBile» was celebrated at the Institute for Internal Medicine Monday May 6th.
Professor Tom Hemming Karlsen recieved the prestigues 2025 Max Siurala Award.
The European Research Council (ERC) has awarded an ERC Consolidator Grant of 2 million Euros to Professor Johannes Espolin Roksund Hov, who aims to investigate the interaction between gut bacteria and the development of severe liver diseases.
There is still much we do not know about Primary Sclerosing Cholangitis (PSC). New research provides another piece in the scientific puzzle.
